3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
8
Neoplasms
2
Multiple Myeloma
2
HER2-positive Breast Cancer
2
Endometrial Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
HR+/HER2+ Early Breast Cancer
1
Glioma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Cytarabine
5
Whole-Body Irradiation
3
Specimen Handling
3
Injections
3
CPX-351
3
Blood Specimen Collection
3
venetoclax
2
luspatercept
2
ivosidenib
2
fludarabine phosphate
2
fludarabine
2
decitabine and cedazuridine drug combination
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Melphalan
2
Liposomes
2
Idarubicin
2
Granulocyte Colony-Stimulating Factor
2
Gemtuzumab
2
Filgrastim
2
Daunorubicin
2
Cyclosporine
2
Cyclophosphamide
2
Busulfan
2
Biopsy
2
Azacitidine
2
tocilizumab
1
selinexor
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
pertuzumab
×
30 days
×
Clear all
No trials found.